| Literature DB >> 27056889 |
Abstract
Engineered nanoparticles (ENPs) have been widely applied in industry, commodities, biology and medicine recently. The potential for many related threats to human health has been highlighted. ENPs with their sizes no larger than 100 nm are able to enter the human body and accumulate in organs such as brain, liver, lung, testes, etc, and cause toxic effects. Many references have studied ENP effects on the cells of different organs with related cell apoptosis noted. Understanding such pathways towards ENP induced apoptosis may aid in the design of effective cancer targeting ENP drugs. Such ENPs can either have a direct effect towards cancer cell apoptosis or can be used as drug delivery agents. Characteristics of ENPs, such as sizes, shape, forms, charges and surface modifications are all seen to play a role in determining their toxicity in target cells. Specific modifications of such characteristics can be applied to reduce ENP bioactivity and thus alleviate unwanted cytotoxicity, without affecting the intended function. This provides an opportunity to design ENPs with minimum toxicity to non-targeted cells.Entities:
Keywords: ENP characteristics; apoptosis; cancer cells; cytotoxicity; engineered nanoparticles
Mesh:
Substances:
Year: 2016 PMID: 27056889 PMCID: PMC5130051 DOI: 10.18632/oncotarget.8553
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Uptake of ENPs and their intracellular localizations
ENPs are taken up by animal cells through pinocytosis, caveolae dependent endocytosis, lipid raft composition, clathrin-dependent endocytosis or phagocytosis. ENPs are distributed on the cell membrane, in the endosomes or lysosomes, randomly dispersed in the cytoplasm, interacting with the nuclear membrane, in mitochondria or in the endoplasmic reticulum.
ENPs induced cell apoptosis in different cell lines
| ENPs type | ENPs size | Induced cell apoptosis | Mechanism | Reference |
|---|---|---|---|---|
| Nano-TiO2 | 5-6 nm | mice lung tissue | Oxidative stress | [ |
| AgNP | 25-70 nm | human lung fibroblast (HLF) cell | mitochondrial dysfunction, ROS | [ |
| NiONP | ≤50 nm | human bronchial epithelial cells (BEAS-2B) | SIRT1, caspase3 | [ |
| PAMAM | 45 nm | human lung cells WI-26 VA4 | Intrinsic mitochondrial pathway | [ |
| MWCNOs and MWCNTs | human skin fibroblasts cell (HSF42) | Altered gene expressions | [ | |
| Nano-SiO2 | 15 nm, 30 nm | human keratinocyte HaCaT cells | oxidative stress | [ |
| Nano-TiO2 | 21 nm | HaCaT cells | oxidative damage, intrinsic mitochondrial pathway | [ |
| Cr2O3 NPs | 26.5 nm | HaCaT cells | oxidative DNA damage, caspase 3 | [ |
| NiNPs | 92.32 nm | mouse epidermal JB6 cells | Casepase8/AIF | [ |
| Nano-SiO2 | 15 nm | PC12 cells | oxidative stress | [ |
| Nano-SiO2 | 20 and 50 nm | PC12 cells | oxidative stress | [ |
| Nano-TiO2 | 21 nm | PC12 cells | oxidative stress | [ |
| AgNP | 14 nm | PC12 cells | Caspase8/9 | [ |
| CeO2 NPs | 10-30 nm | monocytes | mitochondria/AIF | [ |
| Nano-TiO2 | 5-6 nm | mice spleen | Oxidative stress, ER stress | [ |
| Nano-TiO2 | 25 nm | human lymphocytes | JNK/p38-caspase 8-Bid pathway | [ |
| CoO-NPs | 62±4 nm | human lymphocytes | TNF-α-caspase 8-P38-caspase 3 | [ |
| PS-NPs | 20 nm, | Caco-2 cells | Oxidative stress | [ |
| AgNPs | 20±2 nm | Caco-2 cells | Oxidative stress, ER stress | [ |
| Nano-ZnO | 80 nm | Mice liver | Oxidative stress, ER stress | [ |
| Nano- SiO2 | 21 nm | hepatic cells L-02 cells | Oxidative stress, p53, Bax | [ |
| Nano-TiO2 | 13-35 nm | human embryonic kidney cell line HEK-293 | Oxidative stress, p53, Bax, caspase 3 | [ |
| Nano-Cu | 15 nm | podocytes | Oxidative stress | [ |
| Nano-Cu | 25-40 nm | Mice kidney | Oxidative stress, intrinsic/extrinsic pathway | [ |
| ZnO NPs | 42 nm | human umbilical vein endothelial cells (HUVECs) | ROS, ER stress | [ |
| MWCNOs | 31.2 nm | HUVECs | ROS, DNA damage | [ |
| SWCNTs | Rat aorta endothelial cells(RAECs) | ROS, mitochondrial pathway | [ | |
| Nano-TiO2 | 50-100 nm | Mice testes | FasL, p38, caspase-3 | [ |
| AgNPs | 10 nm, | Male leydig cell (TM3) | Caspase 3/8/9 | [ |
Figure 2The ENP induced apoptosis pathways The ENPs induce two intrinsic pathways and one extrinsic death receptor pathway
The ENPs generate excessive ROS, resulting in the peroxidation of lipids, protein and DNA. The oxidative stress then triggers mitochondria or ER induced apoptotic pathways. (1) Intrinsic mitochondria pathway. The oxidative DNA damage activates p53 and causes an increase in Bax levels. With the disruption of mitochondrial membrane potential the cytc and AIF is released to the cytoplasm. The cyt c together with caspase 9 and other factors form apoptosome and activate caspase 3, initiating cell apoptosis. The AIF is then translocated to the nucleus and induces DNA breakage. (2) Intrinsic ER pathway. The unfolded protein accumulation induces caspase 12 activation, and p38 MAPK, Chop and JNK are involved in this pathway. (3) Extrinsic pathway. The Fas association with FasL recruits FADD and pro-caspase8 forming DISC and activated caspase 8. Caspase 8 then activates caspase 3, or truncates Bid to tBid. tBid translocates into mitochondria and favors the release of Cyt C. MT: mitochondria. ER: endoplasmic reticulum. Cyt C: cytochrome c. DISC: death inducing signaling complex. tBid: truncated Bid.
ENPs induced cancer cell apoptosis
| ENPs type | ENPs size | Apoptosis in cancer cell | phenotype | Reference |
|---|---|---|---|---|
| AgNP | 22 nm | human breast cancer cell line (MCF-7) | Cell shrinkage, nuclear condensation and fragmentation, DNA break up, apoptotic bodies | [ |
| AgNP | Not mentioned | human lung carcinoma cell line A549 | Increased Caspase 3/7/9 activities and mitochondrial depolarization, high levels of Bax, Smac/BIABLO, | [ |
| AgNP | 5 to 25 nm | human colon cancer cell (COLO 205) | chromatin condensation and nuclear fragmentation, MMP loss, increased ROS levels | [ |
| AgNP | 25 to 39 nm | human colon cancer cell(HCT-15, HT-29) | cell cycle arrest in G0/G1 phase | [ |
| AgNP | 7.5±2.5 nm | ovarian carcinoma cell line | DNA damage | [ |
| ,nano-Cr2O3 | 60 nm | Human lung cancer cell line | Increased ROS levels and antioxidant activities, caspase 3 activation | [ |
| Au-Fe2O3 NPs | 44.8±11.8 nm | human lung cancer HepG2 cells | shrinkage, budding and apoptotic body formation, increased ·OH and caspase 3 levels | [ |
| Nano-TiO2 | 20-50 nm | A549 | Increased ROS, decreased ATP | [ |
| nano-HAP | <50 nm | human gastric cancer SGC-7901 cells | chromatin condensation and margination, cell blebbing and vacuoles, decreased mitochondrial membrane potential, release of Cyt C, increased caspase 3/9 | [ |
| nano-HAP | 20 nm, 80 nm | human osteosarcoma MG-63 cells | nuclear fragmentation, formation of dense rounded apoptotic bodies, increased caspase 9 | [ |
| nano-HAP | <20 nm | mice leukemia P388 cells | irregular nucleus, ER expansion, mitochondrial swelling and collapse, cell arrest in G1 phase | [ |
| MoO3 nanoplate | Width of 100-200 nm, length of 400 nm | human invasive breast cancer iMCF-7 cells | activated caspase 8 and caspase 9, increased ROS levels and declined mitochondrial membrane potential, condensed and fragmented chromatins | [ |
| Nano-Se | 59 nm | A357 melanoma cells | DNA fragmentation, phosphatidylserine translocation, | [ |
| Realgar nanoparticles | 80 nm | rat glioma C6 cells | Cell arrest in G0/G1 phases, increased Bax/Bcl2 ratio | [ |
Figure 3ENPs can be used as nano-carriers in cancer therapy
A. ENPs were constructed with nucleus-targets and caused its deformation and induced apoptotic bodies. B. ENPs were constructed with MT-targets and caused ROS-dependent oxidative damages, cyt C-dependent apoptosis, and AIF induced nucleus breakage. C. ENPs were constructed with cyt C which were able to induce caspase 3/8/9-dependent apoptosis. D. ENPs were constructed with ER targets and induced caspase 12-dependent apoptosis. E. ENPs were constructed with cancer drugs that were not able to be taken into cancer cells. MT: mitochondria. ER: endoplasmic reticulum. cyt C: cytochrome c.
| Abbreviations | Full name |
|---|---|
| NPs | nanoparticles |
| ENPs | engineered nanoparticles |
| BBB | blood-brain barrier |
| BTB | blood-testis barrier |
| CNS | central nervous system |
| AgNPs | silver nanoparticles |
| CNTs | carbon nanotubes |
| ROS | reactive oxygen species |
| TEM | transmission electron microscopy |
| SEM | scanning electron microscopy |
| ER | the endoplasmic reticulum |
| SIRT1 | sirtuin 1 |
| HaCaT | human keratinocyte cells |
| FADD | Fas-associated proteins with death domain |
| DISC | death including signaling complex |
| AIF | apoptosis-inducing factor |
| PC12 | dopaminergic neuron cells |
| GSH | glutathione |
| MDA | methane dicarboxylic aldehyde |
| SOD | superoxide dismutase |
| N-MPG | N-(mercaptopropinyl)-glycine |
| t-Bid | Truncated-Bid |
| MAPK | mitogen-activated protein kinase |
| JNK | cJun N-terminal kinase |
| LDH | lactate dehydrogenase |
| CAT | catalase |
| H2O2 | hydrogen peroxide |
| CHOP | C/EBF-homologue protein |
| UPR | unfolded protein response |
| DISC | death inducing signaling complex |
| Nrf2 | nuclear factor erythroid 2 (NF-E2)-related factor 2 |
| cyt C | cytochrome c |